Lyell Wealth Management LP Increases Stake in Thermo Fisher Scientific Inc. $TMO

Lyell Wealth Management LP increased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 34,223 shares of the medical research company’s stock after buying an additional 1,453 shares during the period. Thermo Fisher Scientific comprises 1.4% of Lyell Wealth Management LP’s investment portfolio, making the stock its 20th largest holding. Lyell Wealth Management LP’s holdings in Thermo Fisher Scientific were worth $19,831,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. Gateway Wealth Partners LLC purchased a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at approximately $201,000. Picton Mahoney Asset Management increased its position in shares of Thermo Fisher Scientific by 29.6% in the 4th quarter. Picton Mahoney Asset Management now owns 45,459 shares of the medical research company’s stock valued at $26,341,000 after purchasing an additional 10,382 shares during the last quarter. Mill Capital Management LLC increased its position in shares of Thermo Fisher Scientific by 0.6% in the 4th quarter. Mill Capital Management LLC now owns 80,826 shares of the medical research company’s stock valued at $46,835,000 after purchasing an additional 521 shares during the last quarter. Meiji Yasuda Life Insurance Co increased its position in shares of Thermo Fisher Scientific by 1.1% in the 4th quarter. Meiji Yasuda Life Insurance Co now owns 5,068 shares of the medical research company’s stock valued at $2,937,000 after purchasing an additional 54 shares during the last quarter. Finally, Empowered Funds LLC increased its position in shares of Thermo Fisher Scientific by 37.1% in the 4th quarter. Empowered Funds LLC now owns 26,560 shares of the medical research company’s stock valued at $15,390,000 after purchasing an additional 7,188 shares during the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Stock Down 1.4%

Shares of NYSE:TMO opened at $475.12 on Friday. The stock has a market cap of $176.56 billion, a P/E ratio of 26.12, a P/E/G ratio of 2.13 and a beta of 0.88. The firm has a fifty day moving average price of $479.68 and a 200 day moving average price of $528.09. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, topping the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The company had revenue of $11.01 billion during the quarter, compared to analysts’ expectations of $10.86 billion. During the same quarter last year, the business earned $5.15 EPS. The business’s revenue was up 6.2% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 24.86 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Monday, June 15th will be paid a $0.47 dividend. This represents a $1.88 annualized dividend and a dividend yield of 0.4%. The ex-dividend date is Monday, June 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.34%.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. Morgan Stanley restated an “overweight” rating and issued a $620.00 target price on shares of Thermo Fisher Scientific in a report on Monday, April 27th. HSBC cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and lowered their target price for the company from $670.00 to $540.00 in a report on Wednesday, June 3rd. Stifel Nicolaus lowered their target price on shares of Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating for the company in a report on Friday, April 24th. Jefferies Financial Group upgraded shares of Thermo Fisher Scientific to a “strong-buy” rating in a report on Friday, April 24th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Thermo Fisher Scientific in a report on Wednesday, April 8th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $608.95.

Insider Activity at Thermo Fisher Scientific

In other news, COO Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction on Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the sale, the chief operating officer owned 25,051 shares in the company, valued at approximately $11,590,095.66. This trade represents a 1.57% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.